What's the earliest date this could be brought to market?
2014, IMO.
Do you think this is efficient use of shareholder funds?
Yes, the cost of funding this phase-3 program is no problem at all for VTRX, and the upside is pretty large if these data can help Incivek retain market share.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”